Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Pancreatic Neoplasms 28Carcinoma, Hepatocellular 25Colorectal Neoplasms 23Carcinoma, Non-Small-Cell Lung 13Melanoma 12Stomach Neoplasms 10Colonic Neoplasms 10Liver Neoplasms 9Neoplasm Metastasis 8Squamous Cell Carcinoma of Head and Neck 7Carcinoma, Transitional Cell 7Carcinoma, Renal Cell 7Uterine Cervical Neoplasms 6Rectal Neoplasms 6Ovarian Neoplasms 6Diabetes Mellitus, Insulin-Dependent, 12 6Prostatic Neoplasms 5Lung Neoplasms 5Gastrointestinal Stromal Tumors 5Esophageal Neoplasms 5Carcinoma 5Urinary Bladder Neoplasms 4Turcot syndrome 4Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Sarcoma 4Mesothelioma 4Endometrial Neoplasms 4Cholangiocarcinoma 4Carcinoma, Merkel Cell 4

Interventions

Specimen Handling 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Xeroderma Pigmentosum × Ipilimumab × Gastrointestinal × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡